Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


3 Ann Intern Med
7 Clin Infect Dis
1 J Immunol
5 J Infect Dis
3 J Virol
1 Lancet
3 MMWR Morb Mortal Wkly Rep
6 N Engl J Med
2 Nat Med
3 PLoS Med
9 PLoS One
2 Science
5 Vaccine
1 Virology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Intern Med

  1. MAKI DG
    Recommendations were made for diagnosis and management of allergic reactions to COVID-19 vaccines.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed         Abstract available

    BioNTech/Pfizer vaccine after Oxford/AZ vaccine increased immune response vs. no second vaccine.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed         Abstract available

    The Novavax vaccine had 90% efficacy against COVID-19 >/=7 d after the second dose.
    Ann Intern Med. 2021 Nov 2. doi: 10.7326/ACPJ202111160.
    PubMed         Abstract available


    Covid-19: One in four vaccinated people living in households with a covid-19 case become infected, study finds.
    BMJ. 2021;375:n2638.

    Covid vaccine committee decisions: don't forget JCVI has little or no extra resources to do many times its usual work.
    BMJ. 2021;375:n2646.

  6. SOKOL D
    Covid-19 vaccination should be mandatory for healthcare workers.
    BMJ. 2021;375:n2670.

    Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial.
    BMJ. 2021;375:n2635.

    Taliban lifts ban on polio vaccinations in Afghanistan.
    BMJ. 2021;375:n2656.

  9. SLEAT D, Innes K, Parker I
    Are vaccine passports and covid passes a valid alternative to lockdown?
    BMJ. 2021;375:n2571.

  10. TANNE JH
    Covid-19: US doctors begin administering vaccine to children aged 5-11.
    BMJ. 2021;375:n2693.

    Clin Infect Dis

  11. MARSHALL GS, Ghaswalla PK, Bengtson LGS, Buikema AR, et al
    Low Meningococcal Vaccination Rates Among Patients With Newly Diagnosed Complement Component Deficiencies in the United States.
    Clin Infect Dis. 2021 Oct 28. pii: 6413775. doi: 10.1093.
    PubMed         Abstract available

  12. MALVOLTI S, Pecenka C, Mantel C, Malhame M, et al
    A financial and global demand analysis to inform decisions for funding and clinical development of GBS vaccines for pregnant women.
    Clin Infect Dis. 2021 Nov 2. pii: 6412619. doi: 10.1093.
    PubMed         Abstract available

  13. BRAMUGY J, Mucasse H, Massora S, Vitorino P, et al
    Short and long-term outcomes of GBS invasive disease in Mozambican children: Results of a case cohort and retrospective observational study and implications for future vaccine introduction.
    Clin Infect Dis. 2021 Nov 2. pii: 6388780. doi: 10.1093.
    PubMed         Abstract available

  14. BOSCH W, Cowart JB, Bhakta S, Carter RE, et al
    COVID-19 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida through August 2021.
    Clin Infect Dis. 2021 Nov 2. pii: 6415962. doi: 10.1093.
    PubMed         Abstract available

  15. SHERMAN AC, Desjardins M, Cheng CA, Bausk B, et al
    SARS-CoV-2 mRNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity.
    Clin Infect Dis. 2021 Nov 2. pii: 6415965. doi: 10.1093.
    PubMed         Abstract available

  16. PEREZ Y, Levy ER, Joshi AY, Virk A, et al
    Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.
    Clin Infect Dis. 2021 Nov 3. pii: 6420408. doi: 10.1093.
    PubMed         Abstract available

  17. LIEN CE, Kuo TY, Lin YJ, Lian WC, et al
    Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern.
    Clin Infect Dis. 2021 Nov 5. pii: 6421519. doi: 10.1093.
    PubMed         Abstract available

    J Immunol

  18. LEFEBVRE MN, Drewry LL, Pewe LL, Hancox LS, et al
    Cutting Edge: Subunit Booster Vaccination Confers Sterilizing Immunity against Liver-Stage Malaria in Mice Initially Primed with a Weight-Normalized Dose of Radiation-Attenuated Sporozoites.
    J Immunol. 2021 Oct 29. pii: jimmunol.2100818. doi: 10.4049/jimmunol.2100818.
    PubMed         Abstract available

    J Infect Dis

  19. CAMPBELL N, Verrall AJ, Donkor S, Sutherland JS, et al
    BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia.
    J Infect Dis. 2020 Jul 8. pii: 5868549. doi: 10.1093.
    PubMed         Abstract available

  20. SADOFF J, De Paepe E, Haazen W, Omoruyi E, et al
    Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    J Infect Dis. 2020 Aug 26. pii: 5897745. doi: 10.1093.
    PubMed         Abstract available

  21. MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
    Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
    J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.

  22. SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
    Effectiveness of a third dose of BNT162b2 mRNA vaccine.
    J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
    PubMed         Abstract available

  23. FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
    SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
    J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
    PubMed         Abstract available

    J Virol

  24. VAN HAAREN MM, McCoy LE, Torres JL, Lee W, et al
    Antibodies from rabbits immunized with HIV-1 clade B SOSIP trimers can neutralize multiple clade B viruses by destabilizing the envelope glycoprotein.
    J Virol. 2021 Jun 2:JVI0009421. doi: 10.1128/JVI.00094.
    PubMed         Abstract available

  25. CARTEN JD, Greseth M, Traktman P
    Structure-function analysis of two interacting vaccinia proteins that are critical for viral morphogenesis: L2 and A30.5.
    J Virol. 2021 Nov 3:JVI0157721. doi: 10.1128/JVI.01577.
    PubMed         Abstract available

  26. MIELKE D, Stanfield-Oakley S, Borate B, Fisher LH, et al
    Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.
    J Virol. 2021 Nov 3:JVI0164321. doi: 10.1128/JVI.01643.
    PubMed         Abstract available


  27. ELIAKIM-RAZ N, Leibovici-Weisman Y, Stemmer A, Ness A, et al
    Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >/=60 Years.
    JAMA. 2021 Nov 5. pii: 2786096. doi: 10.1001/jama.2021.19885.

  28. MOSS WJ, Gostin LO, Nuzzo JB
    Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.
    JAMA. 2021 Nov 5. pii: 2786095. doi: 10.1001/jama.2021.20734.

    Understanding Breakthrough Infections Following mRNA SARS-CoV-2 Vaccination.
    JAMA. 2021 Nov 4. pii: 2786040. doi: 10.1001/jama.2021.19063.

  30. TENFORDE MW, Self WH, Adams K, Gaglani M, et al
    Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity.
    JAMA. 2021 Nov 4. pii: 2786039. doi: 10.1001/jama.2021.19499.
    PubMed         Abstract available

  31. ZHONG D, Xiao S, Debes AK, Egbert ER, et al
    Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection.
    JAMA. 2021 Nov 1. pii: 2785919. doi: 10.1001/jama.2021.19996.

  32. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, Yassine HM, et al
    Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar.
    JAMA. 2021 Nov 1. pii: 2785918. doi: 10.1001/jama.2021.19623.
    PubMed         Abstract available


  33. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
    Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
    Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

  34. EMBI PJ, Levy ME, Naleway AL, Patel P, et al
    Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1553-1559.
    PubMed         Abstract available

  35. BOZIO CH, Grannis SJ, Naleway AL, Ong TC, et al
    Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1539-1544.
    PubMed         Abstract available

  36. MBAEYI S, Oliver SE, Collins JP, Godfrey M, et al
    The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021.
    MMWR Morb Mortal Wkly Rep. 2021;70:1545-1552.
    PubMed         Abstract available

    N Engl J Med

  37. URIU K, Kimura I, Shirakawa K, Takaori-Kondo A, et al
    Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    N Engl J Med. 2021 Nov 3. doi: 10.1056/NEJMc2114706.

    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.

  39. WEBER C, von Hundelshausen P, Siess W
    VITT after ChAdOx1 nCoV-19 Vaccination.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.

  40. GREINACHER A, Schonborn L, Thiele T
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.

  41. SCULLY M
    VITT after ChAdOx1 nCoV-19 Vaccination. Reply.
    N Engl J Med. 2021 Nov 3. pii: 10.1056/NEJMc2111026.

  42. MONTO AS
    The Future of SARS-CoV-2 Vaccination - Lessons from Influenza.
    N Engl J Med. 2021 Nov 6. doi: 10.1056/NEJMp2113403.

    Nat Med

  43. TANG P, Hasan MR, Chemaitelly H, Yassine HM, et al
    BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01583.
    PubMed         Abstract available

  44. LEVINE-TIEFENBRUN M, Yelin I, Alapi H, Katz R, et al
    Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
    Nat Med. 2021 Nov 2. pii: 10.1038/s41591-021-01575.
    PubMed         Abstract available

    PLoS Med

  45. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    PubMed         Abstract available

  46. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    PubMed         Abstract available

  47. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    PubMed         Abstract available

    PLoS One

  48. GOMES D, Beyerlein A, Katz K, Hoelscher G, et al
    Is the BNT162b2 COVID-19 vaccine effective in elderly populations? Results from population data from Bavaria, Germany.
    PLoS One. 2021;16:e0259370.
    PubMed         Abstract available

  49. SCHNEIDER JA, Taylor BG, Hotton AL, Lamuda PA, et al
    National variability in Americans' COVID-19 protective behaviors: Implications for vaccine roll-out.
    PLoS One. 2021;16:e0259257.
    PubMed         Abstract available

  50. FANTIN RF, Fraga VG, Lopes CA, de Azevedo IC, et al
    New highly antigenic linear B cell epitope peptides from PvAMA-1 as potential vaccine candidates.
    PLoS One. 2021;16:e0258637.
    PubMed         Abstract available

  51. DOHERTY IA, Pilkington W, Brown L, Billings V, et al
    COVID-19 vaccine hesitancy in underserved communities of North Carolina.
    PLoS One. 2021;16:e0248542.
    PubMed         Abstract available

  52. ANDRASIK MP, Broder GB, Wallace SE, Chaturvedi R, et al
    Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment.
    PLoS One. 2021;16:e0258858.
    PubMed         Abstract available

  53. PRENTOE J, Janitzek CM, Velazquez-Moctezuma R, Goksoyr L, et al
    Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.
    PLoS One. 2021;16:e0255336.
    PubMed         Abstract available

  54. BONAPARTE SC, Adams L, Bakamutumaho B, Barbosa Costa G, et al
    Rabies post-exposure healthcare-seeking behaviors and perceptions: Results from a knowledge, attitudes, and practices survey, Uganda, 2013.
    PLoS One. 2021;16:e0251702.
    PubMed         Abstract available

  55. MUELLER JE, Seanehia J, Yaro S, Trotter CL, et al
    Knowledge, beliefs and practices regarding prevention of bacterial meningitis in Burkina Faso, 5 years after MenAfriVac mass campaigns.
    PLoS One. 2021;16:e0253263.
    PubMed         Abstract available

  56. HYLAND P, Vallieres F, Hartman TK, McKay R, et al
    Detecting and describing stability and change in COVID-19 vaccine receptibility in the United Kingdom and Ireland.
    PLoS One. 2021;16:e0258871.
    PubMed         Abstract available


  57. COHN BA, Cirillo PM, Murphy CC, Krigbaum NY, et al
    SARS-CoV-2 vaccine protection and deaths among US veterans during 2021.
    Science. 2021 Nov 4:eabm0620. doi: 10.1126/science.abm0620.
    PubMed         Abstract available

  58. ELLIOTT P, Haw D, Wang H, Eales O, et al
    Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.
    Science. 2021 Nov 2:eabl9551. doi: 10.1126/science.abl9551.
    PubMed         Abstract available


  59. JEON S, Kelly M, Yun J, Lee B, et al
    Scalable production and immunogenicity of a cholera conjugate vaccine.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01312.
    PubMed         Abstract available

  60. NOWALK MP, D'Agostino HEA, Zimmerman RK, Saul SG, et al
    Agreement among sources of adult influenza vaccination in the age of immunization information systems.
    Vaccine. 2021 Oct 26. pii: S0264-410X(21)01372.
    PubMed         Abstract available

  61. BYRNE T, Patel P, Shrotri M, Beale S, et al
    Trends, patterns and psychological influences on COVID-19 vaccination intention: Findings from a large prospective community cohort study in England and Wales (Virus Watch).
    Vaccine. 2021 Oct 8. pii: S0264-410X(21)01281.
    PubMed         Abstract available

  62. FAN S, Li D, Zhao H, Yu L, et al
    Ameliorated immunity elicited by intradermal inoculation in individuals vaccinated with inactivated SARS-CoV-2 vaccine.
    Vaccine. 2021 Oct 22. pii: S0264-410X(21)01375.
    PubMed         Abstract available

  63. MAZUR A, Benitez S, Chuffart-Finsterwald S, La Rotta R, et al
    COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Vaccine. 2021 Oct 28. pii: S0264-410X(21)01380.


  64. SHI D, Fan B, Sun B, Zhou J, et al
    LDH nanoparticle adjuvant subunit vaccine induces an effective immune response for porcine epidemic diarrhea virus.
    Virology. 2021;565:58-64.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.